AstraZeneca: Is 2017 guidance as rosy as it sounds?

Don't overreact to AstraZeneca's (AZN) rosy outlook, Deutsche Bank says. Among its reasons:

i) AZN has a history of missed long-term forecasts.

ii) What does "broadly in line" with 2013 revenue even mean? "We forecast $24.3B of revenues in 2017, vs. $25.7B in 2013. Is that broadly in line"?

iii) We do not know how much AstraZeneca includes in its internal revenue forecasts for late-stage pipeline drugs, on which we and consensus are relatively cautious.

iv) Revenues are one thing, profitability is another, and there is no reference to Core EPS in its revised guidance.

Firm reiterates Hold rating with price-target just below yesterday's London close.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs